REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal

BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. METHODS: Retrospective...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurol Sci
Hlavní autoři: Batista, S., Nunes, C. C., Cerqueira, J. J., Martins Silva, Ana, Correia de Sá, J., Ferreira, J., Mendonça, M. T., Pinheiro, J., Salgado, V., Correia, A. S., Sequeira, J., Costa, A., Sousa, L.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043899/
https://ncbi.nlm.nih.gov/pubmed/32997282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10072-020-04726-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky